GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » PB Ratio

Champions Oncology (Champions Oncology) PB Ratio : (As of May. 14, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-14), Champions Oncology's share price is $4.64. Champions Oncology's Book Value per Share for the quarter that ended in Jan. 2024 was $-0.15. Hence, Champions Oncology's PB Ratio of today is .

The historical rank and industry rank for Champions Oncology's PB Ratio or its related term are showing as below:

During the past 13 years, Champions Oncology's highest PB Ratio was 958.57. The lowest was 2.18. And the median was 19.08.

CSBR's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.48
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Champions Oncology's average Book Value Per Share Growth Rate was -129.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -5.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Champions Oncology was 334.40% per year. The lowest was -82.50% per year. And the median was 12.10% per year.

Back to Basics: PB Ratio


Champions Oncology PB Ratio Historical Data

The historical data trend for Champions Oncology's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology PB Ratio Chart

Champions Oncology Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.05 19.25 19.37 11.41 14.39

Champions Oncology Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.89 14.39 46.10 780.00 -

Competitive Comparison of Champions Oncology's PB Ratio

For the Biotechnology subindustry, Champions Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's PB Ratio distribution charts can be found below:

* The bar in red indicates where Champions Oncology's PB Ratio falls into.



Champions Oncology PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Champions Oncology's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jan. 2024)
=4.64/-0.151
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Champions Oncology  (NAS:CSBR) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Champions Oncology PB Ratio Related Terms

Thank you for viewing the detailed overview of Champions Oncology's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology (Champions Oncology) Business Description

Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093